stockrow
Friday 6 November 2026
Export IRON’s income statement to Excel — free account
Disc Medicine, Inc.
IRON Healthcare Biotechnology
- EPS
- +2.53%
- Free cash flow
- +7.83%
- Total debt
- +106.5%
Quarter to June 2026, against a year earlier
78.51
0.04
+0.05%
Follow IRON
Alert me
Disc Medicine, Inc. (IRON) EBITDA
Disc Medicine, Inc.'s EBITDA for fiscal 2025 was −$244.3M, compared with −$134.9M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$273.8M. Over the past ten years it has ranged from −$244.3M (fiscal 2025) to −$30.9M (fiscal 2021) — the current reading is the lowest in ten years. EBITDA has fallen for 4 consecutive fiscal years. Disc Medicine, Inc. ranks 549th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$244.3M | — |
| FY2024 | −$134.9M | — |
| FY2023 | −$91.0M | — |
| FY2022 | −$47.4M | — |
| FY2021 | −$30.9M | — |
| FY2020 | −$33.7M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$65.5M | — |
| Mar 2026 | −$70.5M | — |
| Dec 2025 | −$68.5M | — |
| Sep 2025 | −$69.3M | — |
| 22 more quarters | Free account |
Against its own ten years
Low −$244.3M
High −$30.9M
Ten-year median
−$69.2M
Current reading's percentile
17
EBITDA against peers
| Company | EBITDA |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $96.1M |
| TNGX Tango Therapeutics, Inc. compare | −$137.8M |
| PBLS Parabilis Medicines, Inc. compare | −$172.4M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$261.9M |
| IRON Disc Medicine, Inc. | −$273.8M |
| RLAY Relay Therapeutics, Inc. compare | −$311.6M |
| XENE Xenon Pharmaceuticals Inc. compare | −$439.2M |
| DYN Dyne Therapeutics, Inc. compare | −$536.1M |
| VKTX Viking Therapeutics, Inc. compare | −$652.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item